No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
Why Palvella Therapeutics, Inc. (PVLA) Is Surging in 2025
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder